Pharmacology Quiz: Thyroid Hormone Replacement
20 questions · exam conditions
0:00
Thyroid Hormone ReplacementQuestion 1 of 20

A patient with hypothyroidism is adequately treated with levothyroxine, with a TSH of 2.5 mIU/L. They have persistent symptoms of fatigue and ask about adding liothyronine (T3) to their regimen. Which of the following is the most accurate statement to include when counseling this patient?

Combination T4/T3 therapy is the standard of care for patients with persistent symptoms.
Switching to desiccated thyroid extract is a safer way to introduce T3 into the regimen.
Monitoring combination therapy is simpler, as it only requires tracking total T3 levels.
Adding T3 often leads to supraphysiologic T3 peaks, which can increase the risk of cardiac side effects.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Thyroid Hormone Replacement

Practice Thyroid Hormone Replacement in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Thyroid Hormone Replacement, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient with hypothyroidism is adequately treated with levothyroxine, with a TSH of 2.5 mIU/L. They have persistent symptoms of fatigue and ask about adding liothyronine (T3) to their regimen. Which of the following is the most accurate statement to include when counseling this patient?

  1. Combination T4/T3 therapy is the standard of care for patients with persistent symptoms.
  2. Switching to desiccated thyroid extract is a safer way to introduce T3 into the regimen.
  3. Monitoring combination therapy is simpler, as it only requires tracking total T3 levels.
  4. Adding T3 often leads to supraphysiologic T3 peaks, which can increase the risk of cardiac side effects. (correct answer)
Explanation: When evaluating thyroid hormone replacement therapy, you need to understand the pharmacokinetic differences between T4 (levothyroxine) and T3 (liothyronine). T4 has a long half-life and provides steady hormone levels, while T3 has a much shorter half-life and creates significant peaks and troughs in serum concentrations. The correct answer is D because adding T3 to a stable T4 regimen frequently produces supraphysiologic T3 peaks that can trigger cardiac arrhythmias, palpitations, and other cardiovascular complications. The short half-life of T3 means patients experience rapid spikes in thyroid hormone activity that exceed normal physiologic levels, even when the average daily exposure appears appropriate. Option A is incorrect because combination T4/T3 therapy is not standard of care - current guidelines recommend T4 monotherapy as first-line treatment, with combination therapy reserved for specific cases after careful consideration. Option B is wrong because desiccated thyroid extract is not necessarily safer; it still contains T3 and carries similar risks of hormone level fluctuations, plus additional concerns about standardization and potency variability. Option C misrepresents monitoring requirements - combination therapy is actually more complex to monitor because you must track both TSH and T3 levels, and the timing of T3 measurement becomes critical due to its short half-life. For pharmacology exams, remember that shorter half-life drugs generally create more variable serum concentrations and require more frequent dosing or monitoring. When thyroid questions mention "persistent symptoms" with normal TSH, focus on the risks and complexities of combination therapy rather than assuming it's automatically beneficial.

Question 2

A 50-year-old female taking levothyroxine 137 mcg daily has a TSH of 3.1 mIU/L (ref 0.4-4.0 mIU/L). She is started on ferrous sulfate 325 mg three times daily for iron-deficiency anemia, which she takes with her meals. She continues to take her levothyroxine first thing in the morning, 60 minutes before breakfast. What is the most likely impact of this new regimen on her thyroid status?

  1. Her TSH will likely decrease due to iron's effect on T4 to T3 conversion.
  2. Her TSH will remain stable, but her free T4 will increase significantly.
  3. There will be no change because the levothyroxine and iron are separated by her breakfast meal.
  4. Her TSH will likely increase because ferrous sulfate impairs levothyroxine absorption. (correct answer)
Explanation: When you encounter questions about drug interactions with levothyroxine, always consider absorption interference as the primary concern. Levothyroxine has notoriously poor and variable absorption that can be significantly impacted by other medications and supplements. Ferrous sulfate (iron) is one of the most clinically significant interacting substances with levothyroxine. Iron forms chelation complexes with levothyroxine in the gastrointestinal tract, creating insoluble compounds that cannot be absorbed. This interaction occurs regardless of whether the medications are taken simultaneously or separated by meals, as both drugs can remain in the GI tract for extended periods. In this scenario, the patient's TSH of 3.1 mIU/L is already in the upper normal range, suggesting her current levothyroxine dose provides adequate but not excessive thyroid hormone replacement. When iron supplementation reduces levothyroxine absorption, her effective thyroid hormone levels will decrease, causing TSH to rise as the pituitary compensates. Option A is incorrect because iron doesn't enhance T4 to T3 conversion - it actually impairs levothyroxine availability. Option B is wrong because reduced absorption would decrease, not increase, free T4 levels. Option C represents a common misconception; the meal separation doesn't prevent the chelation interaction since both substances can coexist in the GI tract. Key strategy: For levothyroxine interaction questions, remember the major chelating agents: iron, calcium, aluminum, and magnesium. These require separation by 4+ hours, not just meals. Always suspect decreased absorption leading to increased TSH when these interactions occur.

Question 3

A 60-year-old male is being treated with levothyroxine for primary hypothyroidism. His dose was recently adjusted. His labs are: TSH 5.5 mIU/L (ref 0.4-4.0 mIU/L) and free T4 1.9 ng/dL (ref 0.8-1.8 ng/dL). He reports adherence. What is the most likely explanation for this pattern of results?

  1. The patient has central hypothyroidism.
  2. The patient has poor T4 to T3 conversion.
  3. The patient has TSH-secreting pituitary adenoma.
  4. The patient took his levothyroxine dose shortly before the blood draw. (correct answer)
Explanation: When you encounter unusual thyroid function test patterns, always consider timing of medication administration and the pharmacokinetics of levothyroxine. This question tests your understanding of how acute levothyroxine intake affects lab measurements. The pattern here—elevated TSH with high-normal to slightly elevated free T4—is classic for recent levothyroxine ingestion before blood draw. Levothyroxine has peak absorption 1-4 hours after oral administration, causing a temporary spike in serum T4 levels. However, TSH responds much more slowly to changes in thyroid hormone levels due to its longer feedback loop, so it remains elevated from the patient's underlying hypothyroid state. This creates the paradoxical pattern of high TSH with elevated T4. Option A is incorrect because central hypothyroidism presents with low or inappropriately normal TSH alongside low T4—the opposite pattern. Option B doesn't explain the elevated TSH; poor T4 to T3 conversion would typically show normal T4 with low T3, and TSH would be appropriately suppressed if T4 levels were truly adequate. Option C, TSH-secreting adenoma, is extremely rare and would typically cause hyperthyroid symptoms with consistently elevated both TSH and thyroid hormones, not this acute discordant pattern. Remember this key testing principle: always ask patients to hold their levothyroxine dose until after blood draw, or interpret results knowing when the last dose was taken. This prevents misleading lab values that could lead to inappropriate dose adjustments. Most guidelines recommend drawing thyroid function tests before the morning dose.

Question 4

An otherwise healthy 35-year-old male is newly diagnosed with primary hypothyroidism. His weight is 110 kg. Which of the following is the most appropriate initial daily dose of levothyroxine?

  1. 50 mcg
  2. 100 mcg
  3. 175 mcg (correct answer)
  4. 225 mcg
Explanation: The standard initial full replacement dose of levothyroxine in young, healthy adults is approximately 1.6 mcg/kg/day based on ideal body weight. For this 110 kg patient, the calculated dose would be 110 kg * 1.6 mcg/kg = 176 mcg. The closest commercially available dose is 175 mcg. Starting at 50 mcg or 100 mcg would be too low for a full replacement dose in a healthy young adult, requiring prolonged titration. A dose of 225 mcg is excessive and would likely cause hyperthyroidism.

Question 5

A 45-year-old male with primary hypothyroidism has been on a stable dose of levothyroxine 125 mcg daily for two years. His TSH has consistently been around 2.0 mIU/L. He was recently diagnosed with gastroesophageal reflux disease (GERD) and started on omeprazole 40 mg daily. Six weeks later, his follow-up labs show a TSH of 7.8 mIU/L (ref 0.4-4.0 mIU/L). He reports full adherence to all medications.

Which of the following is the most appropriate intervention at this time?

  1. Increase levothyroxine to 150 mcg daily and recheck TSH in 6 weeks.
  2. Separate the administration of levothyroxine and omeprazole by at least 4 hours. (correct answer)
  3. Switch from omeprazole to an H2-receptor antagonist like famotidine.
  4. Discontinue omeprazole and advise lifestyle modifications for GERD.
Explanation: Proton pump inhibitors (PPIs) like omeprazole decrease gastric acid, which is required for the proper dissolution and absorption of levothyroxine. This interaction leads to decreased levothyroxine efficacy and a subsequent rise in TSH. The most appropriate initial step is to manage the drug interaction by separating the administration times by at least 4 hours. Increasing the levothyroxine dose without addressing the absorption issue is a less optimal approach. While switching to an H2RA might cause less impairment, significant interaction still exists. Discontinuing a necessary medication for GERD is not the best first step; managing the interaction should be tried first.

Question 6

A 66-year-old patient is admitted to the ICU with altered mental status, hypothermia (34°C), and bradycardia. Labs reveal a TSH of 95 mIU/L and a very low free T4. Myxedema coma is diagnosed. Which of the following is the most appropriate initial pharmacologic intervention?

  1. Oral levothyroxine 1.6 mcg/kg daily
  2. Intravenous liothyronine 25 mcg every 8 hours
  3. Intravenous levothyroxine 300-500 mcg loading dose (correct answer)
  4. Intravenous hydrocortisone 100 mg every 8 hours as sole therapy
Explanation: Myxedema coma is a life-threatening endocrine emergency requiring immediate thyroid hormone replacement. Due to impaired gastrointestinal absorption in this state, intravenous administration is necessary. The standard of care is an IV loading dose of levothyroxine (T4) of 300-500 mcg to rapidly replenish thyroid hormone stores, followed by a smaller daily maintenance IV dose. Oral therapy is inappropriate due to poor absorption. While IV liothyronine (T3) is sometimes considered as an adjunct, it is not the standard initial monotherapy. IV hydrocortisone is also administered empirically due to the possibility of coexisting adrenal insufficiency, but it does not replace the need for immediate thyroid hormone administration.

Question 7

A patient on levothyroxine 112 mcg daily calls the clinic 3 weeks after their dose was increased from 100 mcg. They state they do not feel any better and request another dose increase. What is the most appropriate response?

  1. Increase the dose to 125 mcg and have them follow up in 3 more weeks for labs.
  2. Schedule a TSH measurement for this week to guide further dose adjustments.
  3. Explain that TSH levels take 4-8 weeks to stabilize after a dose change and recommend re-testing then. (correct answer)
  4. Add a small dose of liothyronine to the current regimen to accelerate symptom improvement.
Explanation: Levothyroxine (T4) has a long half-life of about 7 days. It takes approximately 4-6 half-lives to reach a new steady state after a dose adjustment. Therefore, checking a TSH level before 4-8 weeks have passed is premature, as it will not accurately reflect the effect of the new dose. The correct counseling is to explain this pharmacokinetic principle and schedule a lab draw for the appropriate time. Increasing the dose further without an accurate TSH reading is inappropriate. Adding liothyronine is not indicated and does not address the core issue of proper monitoring intervals.

Question 8

A patient with a history of high-risk differentiated thyroid cancer underwent a total thyroidectomy and is on levothyroxine 200 mcg daily. The goal is TSH suppression. Which target TSH range is most appropriate for this patient one year post-operatively, assuming no evidence of disease?

  1. <0.1 mIU/L (correct answer)
  2. 0.1 - 0.5 mIU/L
  3. 0.5 - 2.0 mIU/L
  4. 2.0 - 4.0 mIU/L
Explanation: For patients with high-risk differentiated thyroid cancer, the therapeutic goal is to suppress TSH to very low levels to minimize the growth stimulus for any potential residual cancer cells. According to American Thyroid Association guidelines, the initial TSH suppression target for high-risk patients is <0.1 mIU/L. For intermediate-risk patients, the goal is typically 0.1-0.5 mIU/L. A goal of 0.5-2.0 mIU/L is for low-risk patients or for long-term follow-up after a period of more aggressive suppression. A TSH of 2.0-4.0 mIU/L is within the normal range for the general population but represents inadequate suppression for this patient.

Question 9

A 32-year-old female at 10 weeks gestation is being managed for pre-existing Hashimoto's thyroiditis. Prior to conception, she was stable on levothyroxine 100 mcg daily with a TSH of 1.8 mIU/L. Her current labs show a TSH of 4.5 mIU/L. What is the most appropriate adjustment to her levothyroxine regimen?

  1. Increase the dose by 10-15% and recheck TSH in 4 weeks.
  2. Increase the dose by 25-30% and recheck TSH in 4 weeks. (correct answer)
  3. Maintain the current dose and recheck TSH in the second trimester.
  4. Add liothyronine 5 mcg daily to her current regimen.
Explanation: During pregnancy, levothyroxine requirements typically increase by 25-50% due to increased thyroid binding globulin (TBG), placental deiodinase activity, and transplacental T4 passage. The goal TSH in the first trimester is <2.5 mIU/L. Since her TSH is elevated, an immediate dose increase is warranted. A 25-30% increase is the standard recommendation upon confirmation of pregnancy or elevation of TSH. A 10-15% increase may be insufficient. Maintaining the current dose is inappropriate as it could lead to maternal and fetal complications. Adding T3 (liothyronine) is not recommended during pregnancy.

Question 10

A 28-year-old woman on a stable dose of levothyroxine 75 mcg daily for the past year begins taking an oral contraceptive pill containing ethinyl estradiol. Six weeks later, what is the most likely expected change in her thyroid function tests, assuming her levothyroxine dose has not been adjusted?

  1. Decreased total T4, normal free T4, and normal TSH.
  2. Increased total T4, decreased free T4, and increased TSH. (correct answer)
  3. Normal total T4, increased free T4, and decreased TSH.
  4. Increased total T4, normal free T4, and normal TSH.
Explanation: Estrogens increase the synthesis of thyroid-binding globulin (TBG), the primary carrier protein for thyroid hormones. This leads to a greater proportion of thyroid hormone being bound, which decreases the free (active) T4 concentration. The pituitary gland responds to the lower free T4 by increasing TSH secretion. The total T4 level may be elevated due to the increased amount of bound hormone. Consequently, women on levothyroxine who start estrogen therapy often require a dose increase to maintain a euthyroid state. The lab profile would show a high TSH and a low or low-normal free T4.

Question 11

A patient with a history of high-risk differentiated thyroid cancer underwent a total thyroidectomy and is on levothyroxine 200 mcg daily. The goal is TSH suppression. Which target TSH range is most appropriate for this patient one year post-operatively, assuming no evidence of disease?

  1. <0.1 mIU/L (correct answer)
  2. 0.1 - 0.5 mIU/L
  3. 0.5 - 2.0 mIU/L
  4. 2.0 - 4.0 mIU/L
Explanation: For patients with high-risk differentiated thyroid cancer, the therapeutic goal is to suppress TSH to very low levels to minimize the growth stimulus for any potential residual cancer cells. According to American Thyroid Association guidelines, the initial TSH suppression target for high-risk patients is <0.1 mIU/L. For intermediate-risk patients, the goal is typically 0.1-0.5 mIU/L. A goal of 0.5-2.0 mIU/L is for low-risk patients or for long-term follow-up after a period of more aggressive suppression. A TSH of 2.0-4.0 mIU/L is within the normal range for the general population but represents inadequate suppression for this patient.

Question 12

A 62-year-old male with a history of a pituitary macroadenoma status-post transsphenoidal surgery is being evaluated for central hypothyroidism. Which set of laboratory findings and corresponding interpretation is most accurate for monitoring his thyroid hormone replacement therapy?

  1. TSH should be maintained in the lower half of the normal range (0.4-2.0 mIU/L).
  2. Free T4 should be maintained in the upper half of the normal reference range. (correct answer)
  3. Total T4 is the preferred marker due to its stability and long half-life.
  4. TSH is the most sensitive marker and should be the primary target for dose adjustments.
Explanation: In central (secondary or tertiary) hypothyroidism, the pituitary gland cannot produce TSH reliably. Therefore, TSH is not a useful marker for monitoring the adequacy of levothyroxine replacement. Instead, dose adjustments are guided by the free T4 level. The goal is to maintain the free T4 in the upper half of the normal reference range to ensure euthyroidism and avoid both under-treatment and over-treatment. Using TSH as a target would be misleading and is the standard of care only for primary hypothyroidism. Total T4 can be affected by binding protein concentrations and is less accurate than free T4.

Question 13

A 28-year-old woman on a stable dose of levothyroxine 75 mcg daily for the past year begins taking an oral contraceptive pill containing ethinyl estradiol. Six weeks later, what is the most likely expected change in her thyroid function tests, assuming her levothyroxine dose has not been adjusted?

  1. Decreased total T4, normal free T4, and normal TSH.
  2. Increased total T4, decreased free T4, and increased TSH. (correct answer)
  3. Normal total T4, increased free T4, and decreased TSH.
  4. Increased total T4, normal free T4, and normal TSH.
Explanation: Estrogens increase the synthesis of thyroid-binding globulin (TBG), the primary carrier protein for thyroid hormones. This leads to a greater proportion of thyroid hormone being bound, which decreases the free (active) T4 concentration. The pituitary gland responds to the lower free T4 by increasing TSH secretion. The total T4 level may be elevated due to the increased amount of bound hormone. Consequently, women on levothyroxine who start estrogen therapy often require a dose increase to maintain a euthyroid state. The lab profile would show a high TSH and a low or low-normal free T4.

Question 14

A 48-year-old male on a stable dose of levothyroxine 150 mcg daily is diagnosed with tuberculosis and begins a multi-drug regimen that includes rifampin. What is the anticipated effect on his thyroid hormone replacement needs?

  1. The levothyroxine dose will likely need to be decreased due to reduced protein binding.
  2. He should be switched to liothyronine as its metabolism is unaffected by rifampin.
  3. No change in levothyroxine dose is expected as rifampin does not interact.
  4. The levothyroxine dose will likely need to be increased due to enhanced hepatic metabolism. (correct answer)
Explanation: When you encounter questions about drug interactions affecting thyroid hormone replacement, focus on how the interacting drug alters levothyroxine metabolism or absorption. Rifampin is a potent inducer of hepatic cytochrome P450 enzymes, particularly CYP3A4. When rifampin induces these enzymes, it accelerates the metabolism of many drugs, including levothyroxine. This enhanced hepatic clearance means levothyroxine is broken down more rapidly, reducing its effective concentration in the blood. To maintain therapeutic thyroid hormone levels, the levothyroxine dose must be increased to compensate for this accelerated metabolism. Answer D correctly identifies this mechanism. Answer A incorrectly suggests rifampin affects protein binding. While levothyroxine is highly protein-bound, rifampin's primary effect is enzymatic induction, not displacement from binding proteins. Answer B is wrong because switching to liothyronine (T3) doesn't solve the problem—rifampin would similarly enhance T3 metabolism through the same enzymatic pathways. Answer C is simply factually incorrect, as rifampin-levothyroxine is a well-documented, clinically significant drug interaction that requires dose adjustments. Remember this pattern: rifampin is one of the classic enzyme inducers (along with carbamazepine, phenytoin, and St. John's wort). When you see rifampin in a question with another medication, immediately consider whether that drug might need dose increases due to enhanced metabolism. This interaction is particularly important with narrow therapeutic index drugs like levothyroxine, warfarin, and oral contraceptives.

Question 15

A 62-year-old male with a history of a pituitary macroadenoma status-post transsphenoidal surgery is being evaluated for central hypothyroidism. Which set of laboratory findings and corresponding interpretation is most accurate for monitoring his thyroid hormone replacement therapy?

  1. TSH should be maintained in the lower half of the normal range (0.4-2.0 mIU/L).
  2. Free T4 should be maintained in the upper half of the normal reference range. (correct answer)
  3. Total T4 is the preferred marker due to its stability and long half-life.
  4. TSH is the most sensitive marker and should be the primary target for dose adjustments.
Explanation: In central (secondary or tertiary) hypothyroidism, the pituitary gland cannot produce TSH reliably. Therefore, TSH is not a useful marker for monitoring the adequacy of levothyroxine replacement. Instead, dose adjustments are guided by the free T4 level. The goal is to maintain the free T4 in the upper half of the normal reference range to ensure euthyroidism and avoid both under-treatment and over-treatment. Using TSH as a target would be misleading and is the standard of care only for primary hypothyroidism. Total T4 can be affected by binding protein concentrations and is less accurate than free T4.

Question 16

A 40-year-old female wishes to switch from her current dose of levothyroxine 100 mcg daily to desiccated thyroid extract (DTE). Assuming a standard conversion, which of the following is the most appropriate starting dose of DTE?

  1. 30 mg (1/2 grain) daily
  2. 60 mg (1 grain) daily (correct answer)
  3. 90 mg (1.5 grains) daily
  4. 120 mg (2 grains) daily
Explanation: The generally accepted dose conversion is that 100 mcg of levothyroxine is approximately equivalent to 60-65 mg (1 grain) of desiccated thyroid extract (DTE). Therefore, a starting dose of 60 mg (1 grain) of DTE would be the most appropriate equivalent for a patient switching from 100 mcg of levothyroxine. The other options represent significant under-dosing (30 mg) or over-dosing (90 mg, 120 mg) and would likely result in hypothyroidism or hyperthyroidism, respectively.

Question 17

A patient with hypothyroidism is adequately treated with levothyroxine, with a TSH of 2.5 mIU/L. They have persistent symptoms of fatigue and ask about adding liothyronine (T3) to their regimen. Which of the following is the most accurate statement to include when counseling this patient?

  1. Combination T4/T3 therapy is the standard of care for patients with persistent symptoms.
  2. Switching to desiccated thyroid extract is a safer way to introduce T3 into the regimen.
  3. Monitoring combination therapy is simpler, as it only requires tracking total T3 levels.
  4. Adding T3 often leads to supraphysiologic T3 peaks, which can increase the risk of cardiac side effects. (correct answer)
Explanation: When evaluating thyroid hormone replacement therapy, you need to understand the pharmacokinetic differences between T4 (levothyroxine) and T3 (liothyronine). T4 has a long half-life and provides steady hormone levels, while T3 has a much shorter half-life and creates significant peaks and troughs in serum concentrations. The correct answer is D because adding T3 to a stable T4 regimen frequently produces supraphysiologic T3 peaks that can trigger cardiac arrhythmias, palpitations, and other cardiovascular complications. The short half-life of T3 means patients experience rapid spikes in thyroid hormone activity that exceed normal physiologic levels, even when the average daily exposure appears appropriate. Option A is incorrect because combination T4/T3 therapy is not standard of care - current guidelines recommend T4 monotherapy as first-line treatment, with combination therapy reserved for specific cases after careful consideration. Option B is wrong because desiccated thyroid extract is not necessarily safer; it still contains T3 and carries similar risks of hormone level fluctuations, plus additional concerns about standardization and potency variability. Option C misrepresents monitoring requirements - combination therapy is actually more complex to monitor because you must track both TSH and T3 levels, and the timing of T3 measurement becomes critical due to its short half-life. For pharmacology exams, remember that shorter half-life drugs generally create more variable serum concentrations and require more frequent dosing or monitoring. When thyroid questions mention "persistent symptoms" with normal TSH, focus on the risks and complexities of combination therapy rather than assuming it's automatically beneficial.

Question 18

A 50-year-old female taking levothyroxine 137 mcg daily has a TSH of 3.1 mIU/L (ref 0.4-4.0 mIU/L). She is started on ferrous sulfate 325 mg three times daily for iron-deficiency anemia, which she takes with her meals. She continues to take her levothyroxine first thing in the morning, 60 minutes before breakfast. What is the most likely impact of this new regimen on her thyroid status?

  1. Her TSH will likely decrease due to iron's effect on T4 to T3 conversion.
  2. Her TSH will remain stable, but her free T4 will increase significantly.
  3. There will be no change because the levothyroxine and iron are separated by her breakfast meal.
  4. Her TSH will likely increase because ferrous sulfate impairs levothyroxine absorption. (correct answer)
Explanation: When you encounter questions about drug interactions with levothyroxine, always consider absorption interference as the primary concern. Levothyroxine has notoriously poor and variable absorption that can be significantly impacted by other medications and supplements. Ferrous sulfate (iron) is one of the most clinically significant interacting substances with levothyroxine. Iron forms chelation complexes with levothyroxine in the gastrointestinal tract, creating insoluble compounds that cannot be absorbed. This interaction occurs regardless of whether the medications are taken simultaneously or separated by meals, as both drugs can remain in the GI tract for extended periods. In this scenario, the patient's TSH of 3.1 mIU/L is already in the upper normal range, suggesting her current levothyroxine dose provides adequate but not excessive thyroid hormone replacement. When iron supplementation reduces levothyroxine absorption, her effective thyroid hormone levels will decrease, causing TSH to rise as the pituitary compensates. Option A is incorrect because iron doesn't enhance T4 to T3 conversion - it actually impairs levothyroxine availability. Option B is wrong because reduced absorption would decrease, not increase, free T4 levels. Option C represents a common misconception; the meal separation doesn't prevent the chelation interaction since both substances can coexist in the GI tract. Key strategy: For levothyroxine interaction questions, remember the major chelating agents: iron, calcium, aluminum, and magnesium. These require separation by 4+ hours, not just meals. Always suspect decreased absorption leading to increased TSH when these interactions occur.

Question 19

A 60-year-old male is being treated with levothyroxine for primary hypothyroidism. His dose was recently adjusted. His labs are: TSH 5.5 mIU/L (ref 0.4-4.0 mIU/L) and free T4 1.9 ng/dL (ref 0.8-1.8 ng/dL). He reports adherence. What is the most likely explanation for this pattern of results?

  1. The patient has central hypothyroidism.
  2. The patient has poor T4 to T3 conversion.
  3. The patient has TSH-secreting pituitary adenoma.
  4. The patient took his levothyroxine dose shortly before the blood draw. (correct answer)
Explanation: When you encounter unusual thyroid function test patterns, always consider timing of medication administration and the pharmacokinetics of levothyroxine. This question tests your understanding of how acute levothyroxine intake affects lab measurements. The pattern here—elevated TSH with high-normal to slightly elevated free T4—is classic for recent levothyroxine ingestion before blood draw. Levothyroxine has peak absorption 1-4 hours after oral administration, causing a temporary spike in serum T4 levels. However, TSH responds much more slowly to changes in thyroid hormone levels due to its longer feedback loop, so it remains elevated from the patient's underlying hypothyroid state. This creates the paradoxical pattern of high TSH with elevated T4. Option A is incorrect because central hypothyroidism presents with low or inappropriately normal TSH alongside low T4—the opposite pattern. Option B doesn't explain the elevated TSH; poor T4 to T3 conversion would typically show normal T4 with low T3, and TSH would be appropriately suppressed if T4 levels were truly adequate. Option C, TSH-secreting adenoma, is extremely rare and would typically cause hyperthyroid symptoms with consistently elevated both TSH and thyroid hormones, not this acute discordant pattern. Remember this key testing principle: always ask patients to hold their levothyroxine dose until after blood draw, or interpret results knowing when the last dose was taken. This prevents misleading lab values that could lead to inappropriate dose adjustments. Most guidelines recommend drawing thyroid function tests before the morning dose.

Question 20

A patient with primary hypothyroidism has had persistently elevated TSH levels despite several increases in their levothyroxine dose over the past 6 months. They are now taking 200 mcg daily. They swear they are taking the medication every morning. Upon further questioning, they mention taking it with a bowl of cereal and a cup of coffee. Which of the following is the most likely cause of their refractory hypothyroidism?

  1. Co-administration with food and coffee impairs levothyroxine absorption. (correct answer)
  2. The patient has likely developed antibodies against exogenous T4.
  3. The patient requires combination T4/T3 therapy for adequate conversion.
  4. The current dose is too high, leading to TSH receptor downregulation.
Explanation: Levothyroxine absorption is significantly reduced when taken with food, coffee, or certain medications/supplements (e.g., calcium, iron). The patient's administration of the medication with breakfast is the most common and likely cause for what appears to be treatment resistance. The correct first step is to counsel the patient on proper administration: taking it with water on an empty stomach, at least 30-60 minutes before food or coffee. The other explanations are far less likely. Antibody formation is extremely rare, the need for T3 is a controversial topic reserved for specific cases, and TSH receptor downregulation is not a recognized mechanism for this phenomenon.